Ampio pharmaceuticals' ceo mike martino issues letter to stockholders

Englewood, colo. , june 2, 2022 /prnewswire/ -- ampio pharmaceuticals, inc. (nyse american: ampe), a biopharmaceutical company focused on the advancement of immunomodulatory therapies for the treatment of pain resulting from osteoarthritis in the knee and potentially other articular joints, today released the following letter to stockholders from its chief executive officer, mike martino.
AMPE Ratings Summary
AMPE Quant Ranking